Drug Profile
Xeligekimab - Genrix (Shanghai) Biopharmaceuticals
Alternative Names: GR-1501Latest Information Update: 28 Aug 2023
Price :
$50
*
At a glance
- Originator Genrix (Shanghai) Biopharmaceuticals
- Developer Genrix (Shanghai) Biopharmaceuticals; Peking University People's Hospital
- Class Antipsoriatics; Antirheumatics; Monoclonal antibodies; Recombinant proteins; Skin disorder therapies
- Mechanism of Action IL17A protein inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Axial spondyloarthritis
- No development reported Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 28 Aug 2023 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in China (Parenteral)
- 23 Dec 2021 Genrix (Shanghai) Biopharmaceutical completes enrolment in its phase II trial for Axial spondyloarthritis in China (NCT05162937)
- 28 Sep 2021 No recent reports of development identified for phase-I development in Plaque-psoriasis in China (Parenteral, Injection)